{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T03:47:49Z","timestamp":1782100069591,"version":"3.54.5"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100018217","name":"Universidade Federal De S\u00e3o Paulo","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100018217","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Cocaine use disorder (CUD) remains a major public health challenge with limited effective therapeutic options. Cannabidiol (CBD) has been proposed as a potential treatment due to its neuroprotective and anti-craving properties. This scoping review aims to synthesize and map the existing evidence from clinical trials evaluating CBD\u2019s effects on craving reduction, relapse prevention, cognitive function, and emotional regulation in individuals with CUD. Although CBD was well tolerated and associated with fewer adverse events than conventional pharmacological treatments, clinical studies included in this review did not demonstrate significant efficacy over placebo in reducing cocaine craving, preventing relapse, or improving cognitive performance, despite promising preclinical outcomes. The review also highlights methodological limitations across studies, including variability in dosage, treatment duration, and study design. Although current evidence does not support CBD as a standalone treatment for CUD, its favorable safety profile suggests potential utility within a broader, multimodal therapeutic framework. Future research should prioritize standardized protocols and explore synergistic combinations with behavioral or pharmacological interventions to enhance treatment efficacy.<\/jats:p>","DOI":"10.1007\/s00210-026-05037-x","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T04:49:42Z","timestamp":1770094182000},"page":"9471-9479","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cannabidiol as a treatment for cocaine use disorder: a scoping review"],"prefix":"10.1007","volume":"399","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-2944-7602","authenticated-orcid":false,"given":"Leticia Cust\u00f3dio","family":"dos Santos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5974-0879","authenticated-orcid":false,"given":"Ver\u00f4nica Barros","family":"da Cunha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0068-0061","authenticated-orcid":false,"given":"J\u00e9ssyca Milene","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7065-7484","authenticated-orcid":false,"given":"Larissa Helena Lobo","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7080-3955","authenticated-orcid":false,"given":"Raphael Caio Tamborelli","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,3]]},"reference":[{"key":"5037_CR5","doi-asserted-by":"publisher","unstructured":"American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders (5th ed.). https:\/\/doi.org\/10.1176\/appi.books.9780890425596","DOI":"10.1176\/appi.books.9780890425596"},{"issue":"11","key":"5037_CR1","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1001\/jamapsychiatry.2018.2309","volume":"75","author":"S Bhattacharyya","year":"2018","unstructured":"Bhattacharyya S, Wilson R, Appiah-Kusi E et al (2018) Effect of cannabidiol on medial temporal, midbrain, and striatal dysfunction in people at clinical high risk of psychosis: a randomized clinical trial. JAMA Psychiat 75(11):1107\u20131117. https:\/\/doi.org\/10.1001\/jamapsychiatry.2018.2309","journal-title":"JAMA Psychiat"},{"issue":"4","key":"5037_CR2","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s13311-015-0387-1","volume":"12","author":"EM Blessing","year":"2015","unstructured":"Blessing EM, Steenkamp MM, Manzanares J, Marmar CR (2015) Cannabidiol as a potential treatment for anxiety disorders. Neurotherapeutics 12(4):825\u2013836. https:\/\/doi.org\/10.1007\/s13311-015-0387-1","journal-title":"Neurotherapeutics"},{"issue":"10","key":"5037_CR3","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1001\/jamapsychiatry.2022.2096","volume":"79","author":"MP Bogenschutz","year":"2022","unstructured":"Bogenschutz MP, Ross S, Bhatt S, Baron T, Forcehimes AA, Laska E, Mennenga SE, O\u2019Donnell K, Owens LT, Podrebarac S, Rotrosen J, Tonigan JS, Worth L (2022) Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial. JAMA Psychiat 79(10):953\u2013962. https:\/\/doi.org\/10.1001\/jamapsychiatry.2022.2096","journal-title":"JAMA Psychiat"},{"issue":"1607","key":"5037_CR4","doi-asserted-by":"publisher","first-page":"3364","DOI":"10.1098\/rstb.2011.0389","volume":"367","author":"AC Campos","year":"2012","unstructured":"Campos AC, Moreira FA, Gomes FV, Del Bel EA, Guimar\u00e3es FS (2012) Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders. Philos Trans R Soc Lond B Biol Sci 367(1607):3364\u20133378. https:\/\/doi.org\/10.1098\/rstb.2011.0389","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"issue":"6","key":"5037_CR6","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1136\/jech.52.6.377","volume":"52","author":"SH Downs","year":"1998","unstructured":"Downs SH, Black N (1998) The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health 52(6):377\u2013384. https:\/\/doi.org\/10.1136\/jech.52.6.377","journal-title":"J Epidemiol Community Health"},{"key":"5037_CR7","doi-asserted-by":"publisher","unstructured":"Gallassi AD, de Oliveira AWC, Rodrigues LA et al (2024) Cannabidiol compared to pharmacological treatment as usual for crack use disorder: a feasibility, preliminary efficacy, parallel, double-blind, randomized clinical trial. Int J Ment Health Addict.\u00a0https:\/\/doi.org\/10.1007\/s11469-024-01287-z","DOI":"10.1007\/s11469-024-01287-z"},{"key":"5037_CR21","doi-asserted-by":"publisher","unstructured":"Garcia RCT, Spelta LEW, Udo MSB, Bruno V, Fonseca DA, de Faria Almeida CA, Dos Reis TM, Torres LH, Marcourakis T (2024) Neurotoxicity of crack cocaine exposure: evidence from a systematic review of in vitro and in vivo studies. Arch Toxicol 98(9):2797\u20132816. https:\/\/doi.org\/10.1007\/s00204-024-03782-7","DOI":"10.1007\/s00204-024-03782-7"},{"issue":"19","key":"5037_CR8","doi-asserted-by":"publisher","first-page":"3911","DOI":"10.1007\/s00213-014-3623-1","volume":"231","author":"O George","year":"2014","unstructured":"George O, Koob GF, Vendruscolo LF (2014) Negative reinforcement via motivational withdrawal is the driving force behind the transition to addiction. Psychopharmacology 231(19):3911\u20133917. https:\/\/doi.org\/10.1007\/s00213-014-3623-1","journal-title":"Psychopharmacology"},{"issue":"10","key":"5037_CR9","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1038\/s41386-018-0050-8","volume":"43","author":"G Gonzalez-Cuevas","year":"2018","unstructured":"Gonzalez-Cuevas G, Martin-Fardon R, Kerr TM, Stouffer DG, Parsons LH, Hammell DC, Banks SL, Stinchcomb AL, Weiss F (2018) Unique treatment potential of cannabidiol for the prevention of relapse to drug use: preclinical proof of principle. Neuropsychopharmacology 43(10):2036\u20132045. https:\/\/doi.org\/10.1038\/s41386-018-0050-8","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"5037_CR10","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1001\/jamapsychiatry.2015.2132","volume":"73","author":"BF Grant","year":"2016","unstructured":"Grant BF, Saha TD, Ruan WJ, Goldstein RB, Chou SP, Jung J, Zhang H, Smith SM, Pickering RP, Huang B, Hasin DS (2016) Epidemiology of DSM-5 drug use disorder: results from the national epidemiologic survey on alcohol and related conditions-III. JAMA Psychiat 73(1):39\u201347. https:\/\/doi.org\/10.1001\/jamapsychiatry.2015.2132","journal-title":"JAMA Psychiat"},{"issue":"12","key":"5037_CR11","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1177\/0269881118799954","volume":"32","author":"GL Hay","year":"2018","unstructured":"Hay GL, Baracz SJ, Everett NA, Roberts J, Costa PA, Arnold JC, McGregor IS, Cornish JL (2018) Cannabidiol treatment reduces the motivation to self-administer methamphetamine and methamphetamine-primed relapse in rats. J Psychopharmacol 32(12):1369\u20131378. https:\/\/doi.org\/10.1177\/0269881118799954","journal-title":"J Psychopharmacol"},{"issue":"9","key":"5037_CR12","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1111\/add.14243","volume":"113","author":"C Hindocha","year":"2018","unstructured":"Hindocha C, Freeman TP, Grabski M, Stroud JB, Crudgington H, Davies AC, Das RK, Lawn W, Morgan CJA, Curran HV (2018) Cannabidiol reverses attentional bias to cigarette cues in a human experimental model of tobacco withdrawal. Addiction 113(9):1696\u20131705. https:\/\/doi.org\/10.1111\/add.14243","journal-title":"Addiction"},{"issue":"11","key":"5037_CR13","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1176\/appi.ajp.2019.18101191","volume":"176","author":"YL Hurd","year":"2019","unstructured":"Hurd YL, Spriggs S, Alishayev J, Winkel G, Gurgov K, Kudrich C, Oprescu AM, Salsitz E (2019) Cannabidiol for the reduction of cue-induced craving and anxiety in drug-abstinent individuals with heroin use disorder: a double-blind randomized placebo-controlled trial. Am J Psychiatry 176(11):911\u2013922. https:\/\/doi.org\/10.1176\/appi.ajp.2019.18101191","journal-title":"Am J Psychiatry"},{"key":"5037_CR14","doi-asserted-by":"publisher","first-page":"108948","DOI":"10.1016\/j.neuropharm.2022.108948","volume":"207","author":"S Karimi-Haghighi","year":"2022","unstructured":"Karimi-Haghighi S, Razavi Y, Iezzi D, Scheyer AF, Manzoni O, Haghparast A (2022) Cannabidiol and substance use disorder: dream or reality. Neuropharmacology 207:108948. https:\/\/doi.org\/10.1016\/j.neuropharm.2022.108948","journal-title":"Neuropharmacology"},{"issue":"1","key":"5037_CR15","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/npp.2009.110","volume":"35","author":"GF Koob","year":"2010","unstructured":"Koob GF, Volkow ND (2010) Neurocircuitry of addiction. Neuropsychopharmacology 35(1):217\u2013238. https:\/\/doi.org\/10.1038\/npp.2009.110","journal-title":"Neuropsychopharmacology"},{"issue":"8","key":"5037_CR16","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/S2215-0366(16)00104-8","volume":"3","author":"GF Koob","year":"2016","unstructured":"Koob GF, Volkow ND (2016) Neurobiology of addiction: a neurocircuitry analysis. Lancet Psychiatry 3(8):760\u2013773. https:\/\/doi.org\/10.1016\/S2215-0366(16)00104-8","journal-title":"Lancet Psychiatry"},{"issue":"5","key":"5037_CR17","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1590\/1516-4446-2020-1416","volume":"43","author":"C Meneses-Gaya","year":"2021","unstructured":"Meneses-Gaya C, Crippa JA, Hallak JE, Miguel AQ, Laranjeira R, Bressan RA, Zuardi AW, Lacerda AL (2021) Cannabidiol for the treatment of crack-cocaine craving: an exploratory double-blind study. Braz J Psychiatry 43(5):467\u2013476. https:\/\/doi.org\/10.1590\/1516-4446-2020-1416","journal-title":"Braz J Psychiatry"},{"issue":"9","key":"5037_CR18","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1111\/add.15417","volume":"116","author":"V Mongeau-P\u00e9russe","year":"2021","unstructured":"Mongeau-P\u00e9russe V, Brissette S, Bruneau J, Conrod P, Dubreucq S, Gazil G, Stip E, Jutras-Aswad D (2021) Cannabidiol as a treatment for craving and relapse in individuals with cocaine use disorder: a randomized placebo-controlled trial. Addiction 116(9):2431\u20132442. https:\/\/doi.org\/10.1111\/add.15417","journal-title":"Addiction"},{"issue":"5","key":"5037_CR19","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1097\/ADM.0000000000000959","volume":"16","author":"V Mongeau-P\u00e9russe","year":"2022","unstructured":"Mongeau-P\u00e9russe V, Rizkallah E, Morissette F, Brissette S, Bruneau J, Dubreucq S, Gazil G, Tr\u00e9panier A, Jutras-Aswad D (2022) Cannabidiol effect on anxiety symptoms and stress response in individuals with cocaine use disorder: exploratory results from a randomized controlled trial. J Addict Med 16(5):521\u2013526. https:\/\/doi.org\/10.1097\/ADM.0000000000000959","journal-title":"J Addict Med"},{"issue":"1","key":"5037_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-018-0611-x","volume":"18","author":"Z Munn","year":"2018","unstructured":"Munn Z, Peters MDJ, Stern C, Tufanaru C, McArthur A, Aromataris E (2018) Systematic review or scoping review? Guidance for authors when choosing between a systematic or scoping review approach. BMC Med Res Methodol 18(1):143. https:\/\/doi.org\/10.1186\/s12874-018-0611-x","journal-title":"BMC Med Res Methodol"},{"issue":"47","key":"5037_CR22","doi-asserted-by":"publisher","first-page":"14764","DOI":"10.1523\/JNEUROSCI.4291-09.2009","volume":"29","author":"Y Ren","year":"2009","unstructured":"Ren Y, Whittard J, Higuera-Matas A, Morris CV, Hurd YL (2009) Cannabidiol, a nonpsychotropic component of cannabis, inhibits cue-induced heroin seeking and normalizes discrete mesolimbic neuronal disturbances. J Neurosci 29(47):14764\u201314769. https:\/\/doi.org\/10.1523\/JNEUROSCI.4291-09.2009","journal-title":"J Neurosci"},{"issue":"18","key":"5037_CR23","doi-asserted-by":"publisher","first-page":"5160","DOI":"10.1523\/JNEUROSCI.3387-15.2016","volume":"36","author":"J Renard","year":"2016","unstructured":"Renard J, Loureiro M, Rosen LG, Zunder J, de Oliveira C, Schmid S, Rushlow WJ, Laviolette SR (2016) Cannabidiol counteracts amphetamine-induced neuronal and behavioral sensitization of the mesolimbic dopamine pathway through a novel mTOR\/p70S6 kinase signaling pathway. J Neurosci 36(18):5160\u20135169. https:\/\/doi.org\/10.1523\/JNEUROSCI.3387-15.2016","journal-title":"J Neurosci"},{"key":"5037_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2022.173376","volume":"216","author":"E Rizkallah","year":"2022","unstructured":"Rizkallah E, Mongeau-P\u00e9russe V, Lamanuzzi L, Castenada-Ouellet S, Stip E, Juteau LC, Brissette S, Bruneau J, Dubreucq S, Jutras-Aswad D (2022) Cannabidiol effects on cognition in individuals with cocaine use disorder: exploratory results from a randomized controlled trial. Pharmacol Biochem Behav 216:173376. https:\/\/doi.org\/10.1016\/j.pbb.2022.173376","journal-title":"Pharmacol Biochem Behav"},{"issue":"3","key":"5037_CR25","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/s0376-8716(97)00099-9","volume":"47","author":"DD Simpson","year":"1997","unstructured":"Simpson DD, Joe GW, Rowan-Szal GA (1997) Drug abuse treatment retention and process effects on follow-up outcomes. Drug Alcohol Depend 47(3):227\u2013235. https:\/\/doi.org\/10.1016\/s0376-8716(97)00099-9","journal-title":"Drug Alcohol Depend"},{"key":"5037_CR26","unstructured":"United Nations Office on Drugs and Crime (2024) World Drug Report 2024. United Nations. https:\/\/www.unodc.org\/unodc\/en\/dataand-analysis\/world-drug-report-2024.html"},{"key":"5037_CR27","doi-asserted-by":"publisher","first-page":"1183740","DOI":"10.3389\/fpsyt.2023.1183740","volume":"14","author":"R Zafar","year":"2023","unstructured":"Zafar R, Siegel M, Harding R, Barba T, Agnorelli C, Suseelan S, Roseman L, Wall M, Nutt DJ, Erritzoe D (2023) Psychedelic therapy in the treatment of addiction: the past, present and future. Front Psychiatry 14:1183740. https:\/\/doi.org\/10.3389\/fpsyt.2023.1183740","journal-title":"Front Psychiatry"},{"key":"5037_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00259","volume":"8","author":"AW Zuardi","year":"2017","unstructured":"Zuardi AW, Rodrigues NP, Silva AL, Bernardo SA, Hallak JEC, Guimar\u00e3es FS, Crippa JAS (2017) Inverted U-shaped dose-response curve of the anxiolytic effect of cannabidiol during public speaking in real life. Front Pharmacol 8:259. https:\/\/doi.org\/10.3389\/fphar.2017.00259","journal-title":"Front Pharmacol"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05037-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05037-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05037-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T02:57:56Z","timestamp":1782097076000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05037-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,3]]},"references-count":28,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["5037"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05037-x","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,3]]},"assertion":[{"value":"2 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}